Diabetic retinopathy: Pathogenic mechanisms and current treatments

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 5, Issue 3, 2011, Pages 165-172

  Chistiakov, Dimitry A ^a  

^a STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

Author keywords

Diabetic maculopathy; Diabetic retinopathy; Emerging therapeutic targets; Management

Indexed keywords

AFLIBERCEPT; ALPHA TOCOPHEROL; AMINOGUANIDINE; ASCORBIC ACID; BEVACIZUMAB; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALOG; ESBA 105; FENOFIBRATE; INDAPAMIDE; INFLIXIMAB; LISONOPRIL; LOSARTAN; NEPAFENAC; PEGAPTANIB; PERINDOPRIL; RANIBIZUMAB; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; SIMVASTATIN; SOMATOMEDIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CATARACT; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; ENDOPHTHALMITIS; GLAUCOMA; GLYCATION; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TISSUE INJURY;

ADULT; AGED; BLINDNESS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MIDDLE AGED; YOUNG ADULT;

EID: 84861331685     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2012.02.025     Document Type: Review

References (130)

1. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 2 1998 1414 1431
2. WHO. 2011 [cited 2011]. Available from: http://www.who.int/diabetes/en/.
3. Y. Wang, A. Fawzi, O. Tan, J. Gil-Flamer, and D. Huang Retinal blood flow detection in diabetic patients by Doppler Fourier domain optical coherence tomography Opt Express 17 2009 4061 4073
4. C. Hudson The clinical features and classification of diabetic retinopathy Ophthalmic Physiol Opt 16 Suppl. 2 1996 S43 S48
5. J.T. Durham, and I.M. Herman Microvascular modifications in diabetic retinopathy Curr Diab Rep 11 2011 253 264
6. C.P. Wilkinson, F.L. Ferris 3rd, R.E. Klein, P.P. Lee, C.D. Agardh, and M. Davis Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales Ophthalmology 110 2003 1677 1682
7. S. Resnikoff, D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, and G.P. Pokharel Global data on visual impairment in the year 2002 Bull World Health Organ 82 2004 844 851
8. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 1984 527 532
9. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 102 1984 520 526
10. M.D. Davis, M.R. Fisher, R.E. Gangnon, F. Barton, L.M. Aiello, and E.Y. Chew Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18 Invest Ophthalmol Vis Sci 39 1998 233 252
11. The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 1993 977 986
12. I.M. Stratton, E.M. Kohner, S.J. Aldington, R.C. Turner, R.R. Holman, and S.E. Manley UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis Diabetologia 44 2001 156 163
13. The DRVS Research Group Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1 Ophthalmology 92 1985 492 502
14. The UKPDS Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
15. The DCCT Research Group Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial Arch Ophthalmol 116 1998 874 886
16. R. Klein, B.E. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy Arch Ophthalmol 112 1994 1217 1228
17. R. Klein, M.D. Knudtson, K.E. Lee, R. Gangnon, and B.E. Klein The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes Ophthalmology 115 2008 1859 1868
18. L.P. Aiello, T.W. Gardner, G.L. King, G. Blankenship, J.D. Cavallerano, and F.L. Ferris 3rd Diabetic retinopathy Diabetes Care 21 1998 143 156
19. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema Ophthalmology 91 1984 1464 1474
20. R. Klein, and B.E. Klein Blood pressure control and diabetic retinopathy Br J Ophthalmol 86 2002 365 367
21. The UKPDS Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 317 1998 703 713
22. B.E. Klein, S.E. Moss, and R. Klein Is menarche associated with diabetic retinopathy? Diabetes Care 13 10 1990 1034 1038
23. B.E. Klein, S.E. Moss, and R. Klein Effect of pregnancy on progression of diabetic retinopathy Diabetes Care 13 1990 34 40
24. The DCCT Research Group Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group Diabetes Care 23 2000 1084 1091
25. S. Patel, H. Chen, N.H. Tinkham, and K. Zhang Genetic susceptibility of diabetic retinopathy Curr Diab Rep 8 2008 257 262
26. K.M. Warpeha, and U. Chakravarthy Molecular genetics of microvascular disease in diabetic retinopathy Eye (Lond) 17 2003 305 311
27. N. Chaturvedi, A.K. Sjolie, J.M. Stephenson, H. Abrahamian, M. Keipes, and A. Castellarin Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus Lancet 351 1998 28 31
28. A. Patel, S. MacMahon, J. Chalmers, B. Neal, M. Woodward, and L. Billot Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
29. G.E. Lang Laser treatment of diabetic retinopathy Dev Ophthalmol 39 2007 48 68
30. H. Lewis The role of vitrectomy in the treatment of diabetic macular edema Am J Ophthalmol 131 2001 123 125
31. J.M. Tarr, K. Kaul, K. Wolanska, E.M. Kohner, and R. Chibber Retinopathy in diabetes S. Ahmed, In diabetes: an old disease, a new insight 2011 Landes Bioscience
32. T.C. Hohman, C. Nishimura, and W.G. Robison Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries Exp Eye Res 48 1989 55 60
33. S.S. Chung, and S.K. Chung Genetic analysis of aldose reductase in diabetic complications Curr Med Chem 10 2003 1375 1387
34. M.A. Ludvigson, and R.L. Sorenson Immunohistochemical localization of aldose reductase. II. Rat eye and kidney Diabetes 29 6 1980 450 459
35. R.L. Engerman, and T.S. Kern Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs Diabetes 42 1993 820 825
36. W.G. Robison Jr., M. Nagata, N. Laver, T.C. Hohman, and J.H. Kinoshita Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor Invest Ophthalmol Vis Sci 30 1989 2285 2292
37. J.P. Szaflik, I. Majsterek, M. Kowalski, P. Rusin, A. Sobczuk, and A.I. Borucka Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy Exp Eye Res 86 2008 647 652
38. S. Amano, S. Yamagishi, Y. Koda, M. Tsuneoka, M. Soejima, and T. Okamoto Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy Med Hypotheses 60 2003 550 551
39. A.W. Stitt The role of advanced glycation in the pathogenesis of diabetic retinopathy Exp Mol Pathol 75 2003 95 108
40. R. Singh, A. Barden, T. Mori, and L. Beilin Advanced glycation end-products: a review Diabetologia 44 2001 129 146
41. S. Yamagishi Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes Exp Gerontol 46 2011 217 224
42. H. Zong, M. Ward, and A.W. Stitt AGEs, RAGE, and diabetic retinopathy Curr Diab Rep 11 2011 244 252
43. H.P. Hammes, S. Martin, K. Federlin, K. Geisen, and M. Brownlee Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy Proc Natl Acad Sci USA 88 1991 11555 11558
44. P.J. Thornalley Use of aminoguanidine (pimagedine) to prevent the formation of advanced glycation endproducts Arch Biochem Biophys 419 2003 31 40
45. N. Shams, and T. Ianchulev Role of vascular endothelial growth factor in ocular angiogenesis Ophthalmol Clin North Am 19 2006 335 344
46. R.B. Bhisitkul Vascular endothelial growth factor biology: clinical implications for ocular treatments Br J Ophthalmol 90 2006 1542 1547
47. R.B. Caldwell, M. Bartoli, M.A. Behzadian, A.E. El-Remessy, M. Al-Shabrawey, and D.H. Platt Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress Curr Drug Targets 6 2005 511 524
48. K. Kaul, A. Hodgkinson, J.M. Tarr, E.M. Kohner, and R. Chibber Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev 6 2010 294 303
49. R. Chibber, B.M. Ben-Mahmud, S. Chibber, and E.M. Kohner Leukocytes in diabetic retinopathy Curr Diabetes Rev 3 2007 3 14
50. J.E. Grunwald, J. DuPont, and C.E. Riva Retinal haemodynamics in patients with early diabetes mellitus Br J Ophthalmol 80 1996 327 331
51. E.M. Kohner, A.M. Hamilton, S.J. Saunders, B.A. Sutcliffe, and C.J. Bulpitt The retinal blood flow in diabetes Diabetologia 11 1975 27 33
52. J.R. MacKinnon, C. O'Brien, K. Swa, P. Aspinall, Z. Butt, and D. Cameron Pulsatile ocular blood flow in untreated diabetic retinopathy Acta Ophthalmol Scand 75 December (6) 1997 661 664
53. S.E. Bursell, A.C. Clermont, B.T. Kinsley, D.C. Simonson, L.M. Aiello, and H.A. Wolpert Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy Invest Ophthalmol Vis Sci 37 1996 886 897
54. G.T. Feke, H. Tagawa, A. Yoshida, D.G. Goger, J.J. Weiter, and S.M. Buzney Retinal circulatory changes related to retinopathy progression in insulin-dependent diabetes mellitus Ophthalmology 92 1985 1517 1522
55. O. Geyer, M. Neudorfer, T. Snir, M. Goldstein, T. Rock, and D.M. Silver Pulsatile ocular blood flow in diabetic retinopathy Acta Ophthalmol Scand 77 5 1999 522 525
56. O. Findl, S. Dallinger, B. Rami, K. Polak, E. Schober, and A. Wedrich Ocular haemodynamics and colour contrast sensitivity in patients with type 1 diabetes Br J Ophthalmol 84 2000 493 498
57. R. Simo, A. Lecube, R.M. Segura, J. Garcia Arumi, and C. Hernandez Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy Am J Ophthalmol 134 2002 376 382
58. M. Grant, B. Russell, C. Fitzgerald, and T.J. Merimee Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization Diabetes 35 1986 416 420
59. V. Haurigot, P. Villacampa, A. Ribera, C. Llombart, A. Bosch, and V. Nacher Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown J Biol Chem 284 2009 22961 22969
60. R.P. Danis, and D.P. Bingaman Insulin-like growth factor-1 retinal microangiopathy in the pig eye Ophthalmology 104 1997 1661 1669
61. A.P. Adamis, D.T. Shima, K.T. Yeo, T.K. Yeo, L.F. Brown, and B. Berse Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells Biochem Biophys Res Commun 193 1993 631 638
62. B. Wirostko, T.Y. Wong, and R. Simo Vascular endothelial growth factor and diabetic complications Prog Retin Eye Res 27 2008 608 621
63. A.P. Adamis, J.W. Miller, M.T. Bernal, D.J. D'Amico, J. Folkman, and T.K. Yeo Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 1994 445 550
64. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, and S.T. Shah Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
65. G.S. Robinson, E.A. Pierce, S.L. Rook, E. Foley, R. Webb, and L.E. Smith Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy Proc Natl Acad Sci USA 93 1996 4851 4856
66. S.A. Madsen-Bouterse, and R.A. Kowluru Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives Rev Endocr Metab Disord 9 2008 315 327
67. R.A. Kowluru, and P.S. Chan Oxidative stress and diabetic retinopathy Exp Diabetes Res 2007 2007 43603
68. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
69. M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
70. G. Giacchetti, L.A. Sechi, S. Rilli, and R.M. Carey The renin-angiotensin-aldosterone system, glucose metabolism and diabetes Trends Endocrinol Metab 16 2005 120 126
71. S. Sarlos, and J.L. Wilkinson-Berka The renin-angiotensin system and the developing retinal vasculature Invest Ophthalmol Vis Sci 46 2005 1069 1077
72. C. Tikellis, C.I. Johnston, J.M. Forbes, W.C. Burns, M.C. Thomas, and R.A. Lew Identification of angiotensin converting enzyme 2 in the rodent retina Curr Eye Res 29 2004 419 427
73. C.B. Engler, H.H. Parving, E.R. Mathiesen, M. Larsen, and H. Lund-Andersen Blood-retina barrier permeability in diabetes during acute ACE-inhibition Acta Ophthalmol (Copenh) 69 1991 581 585
74. C.J. Moravski, D.J. Kelly, M.E. Cooper, R.E. Gilbert, J.F. Bertram, and S. Shahinfar Retinal neovascularization is prevented by blockade of the renin-angiotensin system Hypertension 36 2000 1099 1104
75. P. Anil Kumar, and G. Bhanuprakash Reddy Focus on molecules: aldose reductase Exp Eye Res 85 2007 739 740
76. W. Sun, P.J. Oates, J.B. Coutcher, C. Gerhardinger, and M. Lorenzi A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy Diabetes 55 2006 2757 2762
77. N. Kato, S. Yashima, T. Suzuki, Y. Nakayama, and T. Jomori Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats J Diabet Complications 17 2003 374 379
78. R. Donnelly, I. Idris, and J.V. Forrester Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research Br J Ophthalmol 88 2004 145 151
79. S.V. Joy, A.C. Scates, S. Bearelly, M. Dar, C.A. Taulien, and J.A. Goebel Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications Ann Pharmacother 39 2005 1693 1699
80. The PKC-DRS Group The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial Diabetes 54 2005 2188 2197
81. The PKC-DRS Group Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial Arch Ophthalmol 125 2007 318 324
82. L.P. Aiello, M.D. Davis, A. Girach, K.A. Kles, R.C. Milton, and M.J. Sheetz Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy Ophthalmology 113 2006 2221 2230
83. A.M. Joussen, V. Poulaki, N. Mitsiades, B. Kirchhof, K. Koizumi, and S. Dohmen Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression FASEB J 16 2002 438 440
84. E.M. Kohner Aspirin for diabetic retinopathy BMJ 327 2003 1060 1061
85. K. Bergerhoff, C. Clar, and B. Richter Aspirin in diabetic retinopathy. A systematic review Endocrinol Metab Clin North Am 31 2002 779 793
86. The ETDRS Research Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmology 98 1991 757 765
87. M.C. Gillies, F.K. Sutter, J.M. Simpson, J. Larsson, H. Ali, and M. Zhu Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial Ophthalmology 113 2006 1533 1538
88. Diabetic Retinopathy Clinical Research Network A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Ophthalmology 115 2008 1447 1449
89. B.D. Kuppermann, M.S. Blumenkranz, J.A. Haller, G.A. Williams, D.V. Weinberg, and C. Chou Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema Arch Ophthalmol 125 2007 309 317
90. R.W. Beck, A.R. Edwards, L.P. Aiello, N.M. Bressler, F. Ferris, and A.R. Glassman Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema Arch Ophthalmol 127 2009 245 251
91. T.S. Kern, C.M. Miller, Y. Du, L. Zheng, S. Mohr, and S.L. Ball Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology Diabetes 56 2007 373 379
92. S.M. Hariprasad, D. Callanan, S. Gainey, Y.G. He, and K. Warren Cystoid and diabetic macular edema treated with nepafenac 0.1% J Ocul Pharmacol Ther 23 2007 585 590
93. J.A. Montero, and J.M. Ruiz-Moreno Intravitreal inserts of steroids to treat diabetic macular edema Curr Diabetes Rev 5 2009 26 32
94. M. Ottiger, M.A. Thiel, U. Feige, P. Lichtlen, and D.M. Urech Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer Invest Ophthalmol Vis Sci 50 2009 779 786
95. P.P. Sfikakis, V. Grigoropoulos, I. Emfietzoglou, G. Theodossiadis, N. Tentolouris, and E. Delicha Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study Diabetes Care 33 2010 1523 1528
96. A.C. Keech, P. Mitchell, P.A. Summanen, J. O'Day, T.M. Davis, and M.S. Moffitt Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
97. E.Y. Chew, W.T. Ambrosius, M.D. Davis, R.P. Danis, S. Gangaputra, and C.M. Greven Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
98. P.M. Dodson Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye (Lond) 23 2009 997 1003
99. M. McCombe, S. Lightman, D.J. Eckland, A.M. Hamilton, and S.L. Lightman Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study Eye (Lond) 5 1991 569 575
100. B. Mallet, B. Vialettes, S. Haroche, P. Escoffier, P. Gastaut, and J.P. Taubert Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995 Diabete Metab 18 1992 438 444
101. B.O. Boehm, G.K. Lang, P.M. Jehle, B. Feldman, and G.E. Lang Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy Horm Metab Res 33 2001 300 306
102. M.B. Grant, R.N. Mames, C. Fitzgerald, K.M. Hazariwala, R. Cooper-DeHoff, and S. Caballero The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study Diabetes Care 23 2000 504 549
103. M.I. Davis, S.H. Wilson, and M.B. Grant The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors Horm Metab Res 33 2001 295 299
104. C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, and G. Weckbecker SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 2002 707 716
105. E.T. Cunningham Jr., A.P. Adamis, M. Altaweel, L.P. Aiello, N.M. Bressler, and D.J. D'Amico A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 2005 1747 1757
106. Q.D. Nguyen, S.M. Shah, J.S. Heier, D.V. Do, J. Lim, and D. Boyer Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 116 2009 2175 2181
107. I.U. Scott, A.R. Edwards, R.W. Beck, N.M. Bressler, C.K. Chan, and M.J. Elman A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 114 2007 1860 1867
108. A. Mirshahi, R. Roohipoor, A. Lashay, S.F. Mohammadi, A. Abdoallahi, and H. Faghihi Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial Eur J Ophthalmol 18 2008 263 269
109. M. Soheilian, A. Ramezani, B. Bijanzadeh, M. Yaseri, H. Ahmadieh, and M.H. Dehghan Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema Retina 27 2007 1187 1195
110. M. Soheilian, A. Ramezani, A. Obudi, B. Bijanzadeh, M. Salehipour, and M. Yaseri Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema Ophthalmology 116 2009 1142 1150
111. Q.D. Nguyen, S.M. Shah, D.J. Browning, H. Hudson, P. Sonkin, and S.M. Hariprasad A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration Ophthalmology 116 2009 2141 2148
112. D.V. Do, U. Schmidt-Erfurth, V.H. Gonzalez, C.M. Gordon, M. Tolentino, and A.J. Berliner The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema Ophthalmology 118 2011 1819 1826
113. C.M. Yang, P.T. Yeh, C.H. Yang, and M.S. Chen Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy Am J Ophthalmol 146 2008 211 217
114. P.T. Yeh, C.M. Yang, Y.C. Lin, M.S. Chen, and C.H. Yang Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy Retina 29 2009 768 774
115. M. Saint-Geniez, A.S. Maharaj, T.E. Walshe, B.A. Tucker, E. Sekiyama, and T. Kurihara Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors PLoS One 3 2008 e3554
116. A.K. Sjolie Prospects for angiotensin receptor blockers in diabetic retinopathy Diabetes Res Clin Pract 76 Suppl. 1 2007 S31 S39
117. N. Chaturvedi, M. Porta, R. Klein, T. Orchard, J. Fuller, and H.H. Parving Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394 1402
118. A.K. Sjolie, R. Klein, M. Porta, T. Orchard, J. Fuller, and H.H. Parving Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385 1393
119. M. Mauer, B. Zinman, R. Gardiner, S. Suissa, A. Sinaiko, and T. Strand Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 2009 40 51
120. S.E. Bursell, A.C. Clermont, L.P. Aiello, L.M. Aiello, D.K. Schlossman, and E.P. Feener High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes Diabetes Care 22 1999 1245 1251
121. J.J. Garcia-Medina, M.D. Pinazo-Duran, M. Garcia-Medina, V. Zanon-Moreno, and S. Pons-Vazquez A 5-year follow-up of antioxidant supplementation in type 2 diabetic retinopathy Eur J Ophthalmol 21 2011 637 643
122. E. Lonn, S. Yusuf, B. Hoogwerf, J. Pogue, Q. Yi, and B. Zinman Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy Diabetes Care 25 2002 1919 1927
123. B.B. Gao, A. Clermont, S. Rook, S.J. Fonda, V.J. Srinivasan, and M. Wojtkowski Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation Nat Med 13 2007 181 188
124. M.T. Trese Enzymatic-assisted vitrectomy Eye (Lond) 16 2002 365 368
125. B.D. Kuppermann, E.L. Thomas, M.D. de Smet, and L.R. Grillone Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage Am J Ophthalmol 140 2005 585 597
126. B.D. Kuppermann, E.L. Thomas, M.D. de Smet, and L.R. Grillone Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage Am J Ophthalmol 140 2005 573 584
127. T. Sakuma, M. Tanaka, A. Mizota, J. Inoue, and S. Pakola Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes Invest Ophthalmol Vis Sci 46 2005 3295 3299
128. M.K. Tsilimbaris, V. Pandeleondidis, T. Panagiototglou, V. Arvanitaki, S. Fragiskou, and M. Eleftheriadou Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema Semin Ophthalmol 24 2009 225 230
129. G. Schmidinger, N. Maar, M. Bolz, C. Scholda, and U. Schmidt-Erfurth Repeated intravitreal bevacizumab (Avastin((R))) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation Acta Ophthalmol 89 2011 76 81
130. J.K. Sun Intravitreal anti-VEGF therapy with prompt or deferred laser compared with steroid with prompt laser and prompt laser alone for treatment of diabetic macular edema Curr Diab Rep 11 2011 227 229